S
Seagen Inc
F:SGT
Seagen Inc
F:SGT
Price:
208.6
EUR
Market Closed
Market Cap:
€39.4B
Relative Value
There is not enough data to reliably calculate the relative value of SGT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SGT
Relative Value
Base Case
Not Available
Multiples Across Competitors
SGT Competitors Multiples
Seagen Inc Competitors
Seagen Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402B USD | 6.6 | 96.2 | 15.8 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.9B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.9B USD | 6.2 | 21.3 | 13.3 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.7B USD | 10.4 | 31.6 | 23.9 | 25 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 5.7 | 18.2 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.2B EUR | 11 | 35.2 | 38.3 | 39.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.2B USD | 11.4 | 134.5 | 75 | 83.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
